News

Press Releases

Jun 15, 2021

CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia

Jun 11, 2021

Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting

May 25, 2021

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

May 12, 2021

Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress

Presentations

Jun 15, 2021

CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia

Jun 11, 2021

EHA 2021 Virtual Congress (TDT)

Jun 11, 2021

EHA 2021 Virtual Congress (SCD)

May 12, 2021

Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress

View All Presentations

Events

Wednesday, June 13, 2018 8:00 a.m. PT

CRISPR Therapeutics at Goldman Sachs 39th Annual Global Healthcare Conference

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.